Exact Sciences Completes 54,000 Cologuard Tests during the Second Quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Exact Sciences (EXAS) PT Raised to $20 at Jefferies
July 27, 2016 8:38 AM EDTJefferies analyst Brandon Couillard reiterated a Buy rating and raised his price target on Exact Sciences (NASDAQ: EXAS) to $20.00 (from $13.00) following strong Q2 results.
Couillard commented, "EXAS delivered an exceptionally strong 2Q that exhibited positive progress on essentially every key... More
Exact Sciences (EXAS) Tops Q2 EPS by 9c
July 26, 2016 6:20 AM EDTExact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.46), $0.09 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $21.2 million versus the consensus estimate of $18.54 million.
For earnings history and earnings-related data on Exact Sciences (EXAS) click here.
... More